Lloyd Park’s NovoCure NVCR Stock Holding History

Lloyd Park’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,325	Closed	-$648K	–	85
2022 Q2	$648K	Buy	9,325 +2,625	+39%	+$198K	0.68%	39
2022 Q1	$555K	Buy	6,700 +1,918	+40%	+$141K	0.61%	45
2021 Q4	$359K	Buy	+4,782	New	+$480K	0.2%	84

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lloyd Park's NVCR Position: Q3 2022 in Review

Lloyd Park sold out of NovoCure (NVCR) in Q3 2022, closing a stake of 9,325 shares — an estimated $648K sold.

Lloyd Park first reported a position in NVCR in Q4 2021 and held it in 3 quarters. The position peaked at $648K in Q2 2022. 304 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Lloyd Park reported no remaining NovoCure position as of Q3 2022 after selling out during the quarter.
Lloyd Park sold 9,325 NovoCure shares in Q3 2022, an estimated $648K.
Lloyd Park first reported a position in NovoCure in Q4 2021 and held it in 3 quarters.
Lloyd Park's NovoCure position peaked at $648K in Q2 2022.
304 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Lloyd Park's 13F filing for Q3 2022, filed 14 Nov 2022.